Present and future of pharmaco-arteriothromboprophylaxis in clinical practice. Guidelines of Angiology Section of Slovak Medical Chamber

1. Gavorník P. Všeobecná angiológia. Angiologická propedeutika. Cievne choroby. Bratislava: Univerzita Komenského – Vydavateľstvo UK 2001.

2. Gavorník P. Flebotromboprofylaxia v klinickej praxi. Kardiológia/Cardiology 2010; 19: 98–102.

3. Gavorník P. Vaskulárna endotelová dysfunkcia – etiopatogenéza, základné diagnostické metódy a liečebné možnosti. Gen Angiol 2002; 2: 59–66.

4. Osto E, Coppolino G, Volpe M et al. Restoring the Dysfunctional Endothelium. Curr Pharm Des 2007; 13: 1053–1068.

5. Morel O, Toti F, Hugel B et al. Procoagulant microparticles: disrupting the vascular equation? Arterioscler Thromb Vasc Biol 2006; 26: 2594–2604.

6. Pericleous C, Giles I, Rahman A. Are endothelial microparticles potential markers of vascular dysfunction in the antiphospholipid syndrome? Lupus 2009; 18: 671–675.

7. Kerachian MA, Harvey EJ, Cournoyer D et al. Avascular necrosis of the femoral head: Vascular hypotheses. Endothelium 2006; 13: 237–244.

8. Topaloglu S, Boyaci A, Ayaz S et al. Coagulation, fibrinolytic system activation and Endothelial dysfunction in patients with mitral stenosis and sinus rhytm. Angiology 2007; 58: 85–91.

9. Niboshi A, Hamaoka K, Sakata K et al. Endothelial dysfunction in adult patients with a history of Kawasaki disease. Eur J Pediatr 2008; 167: 189–196.

10. Binotto MA, Maeda NY, Lopez AA. Altered endothelial function following the Fontan procedure. Cardiol Young 2008; 18: 70–74.

11. Remkova A, Kratochvilova H, Durina J. Impact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension. J Human Hypertension 2008; 22: 338–345.

12. Prázný M, Ježková J, Horová E et al. Impaired Microvascular Reactivity and Endothelial Function in Patients with Cushing´s syndrome: Influence of Arterial Hypertension. Physiol Res 2008; 57: 13–22.

13. Gross PL, Aird WC. Endothelium and thrombosis. Semin Thromb Hemost 2000; 26: 463–478.

14. Poderos P. Endothelial dysfunction in the pathogenesis of atherosclerosis. Int Angiol 2002; 21: 109–116.

15. Michelson AD. Platelets. San Diego: Elsevier/Academic Press 2007.

16. Bátorová A. Protidoštičkové lieky – súčasnosť a nové perspektívy. Kardiol Prax 2008; 6: 79–86.

17. Guyatt GH, Akl EA, Crowther M et al. Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians (ACCP) evidence-based clinical practice guidelines (9th edition). Chest 2012; 141 (Suppl 2): e1S-e801S.

18. Hirsh J, Guyatt GH, Albers GW et al. Antithrombotic and thrombolytic therapy: American College of Chest Physicians (ACCP) evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 (Suppl 6): 67S–70S.

19. Gachet C, Aleil B. Testing antiplatelet therapy. Eur Heart J 2008; 10 (Suppl A): A28–A34.

20. Kriška M, Rajec J. Aspirínová dilema. Intern Med 2008; 8: 361–364.

21. Uhrinová A, Pišková T. Klinický význam a liečba hyperurikémie pri cievnych chorobách a cievnych poruchách. Prakt Flebol 2007; 16: 45–48.

22. Hricák V. Aktualizované odporúčania pre používanie klopidogrelu u pacientov s akútnym koronárnym syndrómom, stabilnou angínou pektoris a pri sekundárnej prevencii aterotrombotických príhod. Kardiológia/Cardiology 2009; 18: 87–90.

23. Bates SM, Weitz JI. New antitrombotic drugs. In: Coman RW, Marder VJ, Clowes AW (eds). Hemostasis and Thrombosis. Basic principles of clinical practice. Philadelphia: Lippincott Williams and Wilkins 2006: 1763–1783.

24. Chamorro A. TP receptor antagonism: a new concept in atherothrombosis and stroke prevention. Cerebrovasc Dis 2009; 27: 20–27.

25. Becker RC, Moliterno DJ, Jennings LK et al. TRA-PCI Investigators. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomized, double-blind, placebo-controled phase II study. Lancet 2009; 373: 919–928.

26. Wallentini L. Ticagrelol versus Clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–1057.

27. Hudec R. Prasugrel (Efient). Intern Med 2009; 9 (Suppl 1): S44–S45.

28. Morrow DA, Wiviott SD, White HD et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction: An application of the classification system from the universal definition of myocardial infarction. Circulation 2009; 119: 2758–2764.

29. Remková A. Aktuálne otázky antidoštičkovej liečby kyselinou acetylsalicylovou v primárnej a sekundárnej prevencii cievnych ochorení u diabetikov. Intern Med 2007; 7: 36–39.

30. Pecka M, Malý J. Metabolické a aktivační děje v krevních destičkách a možnosti jejich inhibice. Vnitř Lék 2009; 55: 263–266.

31. Dawson DL, Cutler BS, Hiatt WR et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109: 523–530.

32. Poldermans D, Bax JJ, Boersma et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. The task force for pre­operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur Heart J 2009; 30: 2769–2812.

33. De Caterina R, Husted S, Wallentin L et al. Anticoagulants in heart disease: current status and perspectives. Eur Heart J 2007; 28: ­880–913.

34. Gorog DA, Fuster V. Platelet Function Tests in Clinical Cardiology: Unfulfilled Expectations. J Am Coll Cardiol 2013; 61: 2115–2129.

35. Amin AP, Bachuwar A, Reid KJ et al. Nuisance Bleeding With Prolonged Dual Antiplatelet Therapy After Acute Myocardial Infarction and its Impact on Health Status. J Am Coll Cardiol 2013; 61: 2130–2138.

36. Dauerman HL. The Softer Side of Bleeding.  J Am Coll Cardiol 2013; 61: 2139–2141.

37. Gavorník P. Artériotromboprofylaxia v klini­ckej praxi. Kardiológia/Cardiology 2010; 19: 293–299.

38. Angiolillo DJ. The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes. From Aspirin to the present day. Drugs 2012; 72: 2087–2116.

39. Casado-Arroyo R, Sostres C, Lanas A. Optimizing the Use of Aspirin for Cardiovascular Prevention. Drugs 2013; 73: 803–814.

40. Keating GM. Apixaban: A Review of its Use for Reducing the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation. Drugs 2013; 73: 825–843.

41. Deeks ED. Apixaban. Drugs 2012; 72: ­1271–1291.

42. Brass EP. Intermittent Claudication: New Targets for Drug Development. Drugs 2013; 73: 999–1014.

43. Poulsen BK, Grove EL, Husted SE. New Oral Anticoagulants. Drugs 2012; 72: 1739–1753.

44. Ali FN, Carman TL. Medical Management for Chronic Atherosclerotic Peripheral Arterial Disease. Drugs 2012; 72: 2073–2085.

45. Demchuk AM, Bal S. Thrombolytic Therapy for Acute Ischaemic Stroke. Drugs 2012; 72: 1833–1845.

46. Oldgren J, Wallentin L, Alexander JH et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 2013; 34: 1670–1680.

47. Jeung J, Holinstad M. Newer agents in antiplatelet therapy: a review. J Blood Med 2012; 3: 33–42.

48. Balta S, Demirkol S, Celik T et al. Triple antiplatelet therapy in obese patients undergoing stent implantation. Angiology 2013; 64: ­559–560.

49. Paraskevas KI, Mikhailidis DP, Roussas N et al. Effect of antiplatelet agents, statins and other drugs on vascular access patency rates. Angio­logy 2012; 63: 5–8.

50. Curial M, Nath E, Lang E. Novel antiplatelet agent use for acute coronary syndrom in Emergence Department. Cardiol Res Pract 2013; 2013: 127–270.

51. Wong PF, Chong LY, Stansby G. Antiplatelet Therapy to Prevent Cardiovascular Events and Mortality in Patients With Intermittent Claudication. JAMA 2013; 309: 926–927.

52. Eikelboom JW, Hirsh J, Spencer FA et al. Antiplatelet drugs. In: Guyatt GH, Akl EA, Crowther M et al (eds). Antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians (ACCP) evidence-based clinical practice guidelines. Chest 2012; 141 (Suppl): e89S–e119S.

53. Fox K, Garcia MA, Ardissino D et al. Guidelines on the management on stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341–1381.

54. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999–3054.

55. Van de Werf F, Bax J, Betriu A et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909–2945.

56. Rydén L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: ­88–136.

57. Diskstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388–2442.

58. Regitz-Zagrosek V, Lundquist CB, Borghi C et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 3147–3197.

59. Tendera M, Aboyans V, Bartelink ML et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2851–2906.

60. Gavorník P. Končatinovocievne ischemické choroby. In: Gavorník P, Hrubiško M, Rozborilová E (eds). Diferenciálna diagnostika kardio-vaskulárnych, respiračných a hematologických ochorení. I. Bratislava: Dr. Josef Raabe 2010: 1–92.

61. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28: 2375–2414.

62. Banegas JR, López-Garcia E, Dallongeville J et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J 2011; 32: 2143–2152.

63. Smith SC Jr, Benjamin EJ, Bonow RO et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. A Guideline From the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol 2011; 58: 2432–2446.

64. Rooke TW, Hirsch AT, Misra S et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline). A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 58: 2020–2045.

65. Perk J, De Backer G, Gohlke H et al. Joint ESC Guidelines. European Guidelines on cardiovascular disease prevention in clinical practice (Version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2012; 223: 1–68.

66. McMurray JJ, Adarnopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787–1847.

67. Gavorník P, Dukát A, Gašpar Ľ. Manažment stabilnej anginy pectoris a iných foriem chronickej kardiovaskulárnej artériovej choroby. Vnitř Lék 2012; 58: 29–36.

68. Gavorník P, Gašpar Ľ, Dukát A. Kombinovaná kinezio-flebotromboemboloprofylaxia, mechano-flebotromboemboloprofylaxia a farmako-flebotromboemboloprofylaxia vénovej tromboembólie v internej medicíne. Odporúčania Sekcie angiológov Slovenskej lekárskej komory (SA SLK). Vnitř Lék 2012; 58: 851–855.

69. Kala P, Němec P, Želízko M et al. Revaskularizace myokardu. Perkutánní koronární intervence a aortokoronární bypass. Vnitř Lék 2012; 58 (Suppl 1): S79–S103.

70. Malý J, Pecka M, Malý R. Nová antitrombotika v prevenci žilní tromboembolie a nové protidestičkové léky. Vnitř Lék 2011; 57: 733–739.

71. Widimský P, Rokyta R, Šťásek J et al. Acute coronary syndromes with ongoing myocardial ischemia (ACS with OMI) versus acute coronary syndromes without ongoing ischemia (ACS ­without OMI). The new classification of acute coronary syndromes should replace old classification based on ST segment elevation presence or absence – Expert consensus statement of the Czech Society of Cardiology). Cor Vasa 2013; 55: 290–292.

72. Armstrong PW, Gershlick AH, Goldstein P et al. STREAM Investigative Team. Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction. N Engl J Med 2013; 368: ­1379–1387. DOI: 10.1056/NEJMoa1301092

73. Creager MA, Kaufman JA, Conte MS. Acute Limb Ischemia. N Engl J Med 2012; 366: ­2198–2206. DOI: 10.1056/NEJMcp1006054

74. Borissoff JI, Spronk HMH, Cate H. The Hemostatic System as a Modulator of Atherosclerosis. N Engl J Med 2011; 364: 1746–1760. DOI: 10.1056/NEJMra1011670

75. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 2013; 34: ­2436–2443.

76. Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J 2013; 34: ­2444–2452.

77. Izzo R, de Simone G, Trimarco V et al. Hypertensive target organ damage predicts incident diabetes mellitus. Eur Heart J 2013 eht281 DOI:10.1093/eurheartj/eht281

78. Rydén L, Grant PJ, Anker SD et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34: 3035–3087. DOI: 10.1093/eur­heartj/eht108

79. Jacomella V, Corti N, Husmann M. Novel anticoagulants in the therapy of peripheral arterial and coronary artery disease. Curr Opin Pharmacol 2013; 13: 1–7. http://dx.doi.org/10.1016//j.coph.2012.12.005.